Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jenkem Technology Co., Ltd. (688356.SS)
Beijing, HB, CN
Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol derivative (PEG) products in China and internationally. The company offers high molecular weight polyethylene glycol derivatives comprising branched, methoxylated, bifunctionalized, heterofunctionalized disubstituted, multi-arm, multi-arm heterofunctional disubstituted, amino-polyglycolic, N-terminated polyethylene glycol-modified, and thiol-modified polyethylene glycol PEG products; monodisperse PEG products consisting of methoxy monodisperse PEG derivatives, and monodisperse PEG derivatives with the same functional and heterofunctional groups; click chemistry; lipid nanoparticles delivery system accessories; PEG linkers, such as ADC and PROTAC linkers; PEG medical devices, which include multi-arm PEG derivatives; polyethylene glycol standards; block copolymers; PEG standards; long-acting polypeptide fatty acid side chains, including semaglutide, tirzepatide/icodec, and somapacitan intermediates; and Silkrose injectable cross-linked sodium hyaluronate gel, a passive implantable device used to correct moderate to severe nasolabial folds through subcutaneous injection. It also provides technical services comprising development of synthetic methods, quality research and IND application, analytical method development, and polyethylene glycolization technology services. Jenkem Technology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42% | -7.59% | -22.34% | -25.05% | -12.50% | -8.03% | +0.47% | -33.74% | -66.70% | -44.75% | -44.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+40.1% ★ Q1'26: +14.5% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+108.2% ★ Q1'26: +85.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+9.7% Q1'26: +2.2% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+22.3% ★ Q1'26: +32.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+8.0% ★ Q1'26: +11.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.9% ★ Q1'26: +2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.04× ★ Q1'26: 0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
351.19M
est: 352.00M (-0.2%)
|
407.20M
est: 446.75M (-8.9%)
|
292.12M
est: 249.28M (+17.2%)
|
227.10M
est: 273.00M (-16.8%)
|
318.22M
est: 280.00M (+13.7%)
|
439.00M
439.00M – 439.00M
+56.8% YoY
|
600.00M
600.00M – 600.00M
+36.7% YoY
|
806.00M
806.00M – 806.00M
+34.3% YoY
|
| EBITDA |
215.41M
est: 188.60M (+14.2%)
|
228.05M
est: 239.36M (-4.7%)
|
153.57M
est: 119.42M (+28.6%)
|
75.07M
est: 130.78M (-42.6%)
|
116.35M
est: 134.14M (-13.3%)
|
210.31M
210.31M – 210.31M
+56.8% YoY
|
287.44M
287.44M – 287.44M
+36.7% YoY
|
386.12M
386.12M – 386.12M
+34.3% YoY
|
| EBIT |
202.34M
est: 155.40M (+30.2%)
|
207.99M
est: 197.23M (+5.5%)
|
126.54M
est: 93.92M (+34.7%)
|
33.03M
est: 102.86M (-67.9%)
|
70.86M
est: 105.50M (-32.8%)
|
165.41M
165.41M – 165.41M
+56.8% YoY
|
226.07M
226.07M – 226.07M
+36.7% YoY
|
303.69M
303.69M – 303.69M
+34.3% YoY
|
| Net Income |
175.78M
est: 179.03M (-1.8%)
|
186.83M
est: 223.48M (-16.4%)
|
115.74M
est: 75.33M (+53.7%)
|
29.84M
est: 56.15M (-46.9%)
|
61.70M
est: 53.13M (+16.1%)
|
123.77M
123.77M – 123.77M
+133.0% YoY
|
172.07M
172.07M – 172.07M
+39.0% YoY
|
233.05M
233.05M – 233.05M
+35.4% YoY
|
| SGA |
57.15M
est: 28.49M (+100.6%)
|
63.37M
est: 36.16M (+75.2%)
|
45.91M
est: 41.40M (+10.9%)
|
59.61M
est: 45.34M (+31.5%)
|
29.39M
est: 46.50M (-36.8%)
|
72.91M
72.91M – 72.91M
+56.8% YoY
|
99.65M
99.65M – 99.65M
+36.7% YoY
|
133.86M
133.86M – 133.86M
+34.3% YoY
|
| EPS |
2.93
est: 2.94 (-0.3%)
|
3.11
est: 3.67 (-15.3%)
|
1.92
est: 1.25 (+53.9%)
|
0.49
est: 0.93 (-47.3%)
|
1.02
est: 0.88 (+15.9%)
|
2.05
2.05 – 2.05
+133.0% YoY
|
2.85
2.85 – 2.85
+39.0% YoY
|
3.86
3.86 – 3.86
+35.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 168.5K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 36.2K | 0.29% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.6K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 10.4K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 514.8K | 0.06% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 608.8K | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 827.16 | 0.22% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.5K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.3K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 589.91 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bin Chen | Board Secretary | — | male |
| Chunlei Li | Head of Accounting Agency | — | — |
| Lei Han | Financial Director & Director | — | female |
| Lihong Guo | Deputy GM & Director | — | female |
| Rujun Zhang | Deputy GM & Director | — | female |
| Xuan Zhao | Chairman of the Board & GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688356.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
